Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease - Wikidata - awgldk - TriplyDB

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease

http://www.wikidata.org/entity/Q35897340

about

Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases Total α-synuclein levels in human blood cells, CSF, and saliva determined by a lipid-ELISA.A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease Multiple system atrophy: pathogenic mechanisms and biomarkers.Treatments and compositions targeting α-synuclein: a patent review (2010-2016).Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.Diagnostic utility of cerebrospinal fluid α-synuclein in Parkinson's disease: A systematic review and meta-analysis.Parkinson's Disease: Assay of Phosphorylated α-Synuclein in Skin Biopsy for Early Diagnosis and Association with Melanoma.AlphaLISA detection of alpha-synuclein in the cerebrospinal fluid and its potential application in Parkinson's disease diagnosis.Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease.Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.Alpha-synuclein oligomers: a new hope.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease.Potential clinical utility of multiple system atrophy biomarkers.Phosphorylated α-Synuclein-Copper Complex Formation in the Pathogenesis of Parkinson's Disease.Cerebrospinal Fluid Biomarkers in Highly Exposed PM2.5 Urbanites: The Risk of Alzheimer's and Parkinson's Diseases in Young Mexico City Residents.The Past and the Future of Alzheimer's Disease Fluid Biomarkers.miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease.Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.ELISA method to detect α-synuclein oligomers in cell and animal models.Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease.Phosphotyrosine profiling of human cerebrospinal fluid

P2860

Q28073686-22992365-9D76-4A9C-92DA-82DD3426AA6A Q30392912-6A487CF4-003F-49CC-BD58-0ED01F258AFE Q36109452-AA480C37-F577-44A9-94DA-E9C15EA926DB Q36245278-281EAB35-BF51-4092-A07E-D7773781A0BC Q38813304-431ED8CD-051E-4661-813D-C17EEBE47F36 Q39007523-CC9DD6FE-4E0D-4731-8782-D8C948A59440 Q39010887-A40F9F7E-0FFD-4AAD-824B-EB8210E6B891 Q39466212-CF3F8155-4B15-4E0F-A21F-0781B6D77C7A Q40053985-AE6EB4F7-FD96-4755-9623-36330F6AB427 Q41817806-4EDE3A49-A4FD-4A15-80BB-BAAF1BA4C6E1 Q42347600-8784A95C-31E2-4AEE-B43E-B342FE9E0168 Q42653035-E8BCE14F-3598-4D9E-9F70-1769B40673D5 Q46124320-4080A15A-2FB2-4C79-B4C8-CBD5AE7A8BE8 Q46321755-5DB63501-047D-4DAD-B431-A35809610287 Q47587631-3DC969CB-87F5-44AC-BE42-2556163E4971 Q47653685-8403A982-3532-47B9-AB4D-931F73BC172D Q47663712-E25839A3-064D-4857-AE6C-D46F306291AD Q48246699-B2A5D1F0-B88F-42F5-9985-EF4CDE57A7EE Q48547464-FF7ADA56-B33C-4D9B-9943-0E17DB8538F9 Q52644601-35D881E4-AC85-4403-92BC-B3E99C09B493 Q52801531-1FA21393-913C-4D4F-A5F2-E4232F4C10B9 Q53396870-DCF203CA-7876-4D3F-99BF-A671F2EC741A Q55024134-CF0DF5F3-E890-42BA-960C-CD7D7378FB2E Q55240777-41400ED4-FC36-4D12-9A2C-057303598019 Q58747150-1B391471-1D11-4733-A12E-340B8BA25DDD

P2860

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease

http://www.wikidata.org/entity/Q35897340

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Oligomeric and phosphorylated ...... arkers for Parkinson's disease

@ast

Oligomeric and phosphorylated ...... arkers for Parkinson's disease

@en

type

label

Oligomeric and phosphorylated ...... arkers for Parkinson's disease

@ast

Oligomeric and phosphorylated ...... arkers for Parkinson's disease

@en

prefLabel

Oligomeric and phosphorylated ...... arkers for Parkinson's disease

@ast

Oligomeric and phosphorylated ...... arkers for Parkinson's disease

@en

P1433

Q35897340-C50B10E2-F0DD-43B1-8317-64B94365274E

P1476

Q35897340-457EA3B0-6609-4B95-A0C6-5F37ED16D9B1

P2093

Q35897340-18415820-9AE5-48B9-9470-3B7203FDE74C

Q35897340-29DCE4D0-C3E6-4831-B028-796D7CBC42EE

Q35897340-3968942F-A92E-4771-83B3-323911468B2B

Q35897340-5C2E62DE-0DDB-45F6-A70C-A623474D4257

Q35897340-71B3A3CC-EE88-43FB-8EE1-2645C82FD2CA

Q35897340-80D5D1DF-2521-48A1-8FBE-1596985D71DF

Q35897340-84290979-3AC2-4D5B-8E0D-E1B38C9D0841

Q35897340-89F12440-E833-4B63-8339-D10E69FA5204

Q35897340-8E3A5DE0-0A97-4DDE-96AC-1E220663EE5E

Q35897340-BCE0DE3D-ECC8-4719-B695-43960E790BFC

P2860

Q35897340-0495CCA7-5C01-43E9-8F9D-BAA7B0A9CC1C

Q35897340-095D8297-B744-4A68-B5E4-36739A961C36

Q35897340-09B68BE4-60DC-491C-897B-26A997C26E04

Q35897340-0AB40559-2302-4186-8A26-95D710C1BEA8

Q35897340-0EC082F6-60FD-45FF-BFAA-84689B2B6A77

Q35897340-16AD2787-C51D-40D5-8BB4-794C838D3F95

Q35897340-1C610C40-4F59-466C-A65F-2D7D10CFA0DC

Q35897340-242BF4CA-6801-4968-8FFA-30FFAF53DEB3

Q35897340-24603B1F-0F8A-4478-9BAC-455444B3CE69

Q35897340-2A19C7ED-FC44-4D17-9B26-FD957FBC3F07

P2888

Q35897340-151F1DF7-49D0-4364-BB1A-FB93CA0965F1

P304

Q35897340-1F8695F4-0439-41BB-AA64-0A211634A9E6

P31

Q35897340-E35BD511-2A84-4FA0-B742-4C86023DB66B

P356

Q35897340-404A30A5-23B2-476C-B66C-6CF7AFBED713

P478

Q35897340-12067565-5A77-4869-9F92-A6820D5E9537

P50

Q35897340-758BAAA8-7F07-4BC5-A1CB-DF25A872369F

Q35897340-DC052119-EDE0-46DF-A93D-5CC9C6256EB1

P577

Q35897340-A399443F-82B0-42DA-84D6-4F48DF0370AB

P6179

Q35897340-53484278-F903-4E8A-ACCF-CBBA732E4DF1

P698

Q35897340-B8E19D45-9177-491D-A58C-0C17E3FE0238

P921

Q35897340-251B99D1-23AB-4342-BBD8-6B06F33D7D70

Q35897340-28CE7F34-CC49-4BB7-80B8-CC01D47ACCAC

Q35897340-580F608B-ADB1-4A99-A771-AB9FC4A89580

Q35897340-D860A9FD-F450-40FB-AC38-009B3D8E8DD3

P932

Q35897340-D5F73540-CDE8-40EC-99A9-5565C09E63F4

P356

S13024-016-0072-9

P1433

Molecular Neurodegeneration

P1476

Oligomeric and phosphorylated ...... arkers for Parkinson's disease

@en

P2093

Bared Safieh-Garabedian

http://www.w3.org/2001/XMLSchema#string

Karin D van Dijk

http://www.w3.org/2001/XMLSchema#string

Liliana P Montezinho

http://www.w3.org/2001/XMLSchema#string

Louise B Vesterager

http://www.w3.org/2001/XMLSchema#string

Mustafa T Ardah

http://www.w3.org/2001/XMLSchema#string

Nishant N Vaikath

http://www.w3.org/2001/XMLSchema#string

Nour K Majbour

http://www.w3.org/2001/XMLSchema#string

Omar M A El-Agnaf

http://www.w3.org/2001/XMLSchema#string

Shiji Varghese

http://www.w3.org/2001/XMLSchema#string

Stephen Poole

http://www.w3.org/2001/XMLSchema#string

P2860

Parkinson's disease: clinical features and diagnosis

Alpha-synuclein in Lewy bodies

Alpha-synuclein and tau: teammates in neurodegeneration?

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

Phosphorylated α-synuclein in Parkinson's disease.

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease

Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers.

Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease

P2888

s13024-016-0072-9

P304

7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13024-016-0072-9

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Charlotte Teunissen

Henk W. Berendse

P577

2016-01-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1013554379

http://www.w3.org/2001/XMLSchema#string

P698

26782965

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

phosphorylation

P932

4717559

http://www.w3.org/2001/XMLSchema#string